Navigation Links
Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
Date:11/20/2008

dical need for additional treatment options to combat resistant infections and is the first antibiotic in the dihydrofolate reductase (DHFR) selective inhibitor class to demonstrate efficacy against cSSSIs caused by MRSA. The DHFR class has been proven safe and effective in more than four decades of clinical use.

About Arpida

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the United States. It focuses on the discovery, development and commercialization of novel drugs for the treatment of microbial infections. Arpida has a fully integrated platform for the discovery and development of drug candidates to address the increasing prevalence of resistance of bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), to existing antibiotic therapies. Arpida is currently developing an iclaprim oral formulation as a step-down therapy after intravenous therapy. Apart from the flagship iclaprim program, Arpida has an innovative antifungal treatment in Phase III clinical development as well as several earlier-stage programs (AR-709 and AR-2474).

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

(i) Centers for Disease Control and Prevention Web site. Healthcare-Associated Methic
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
5. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
6. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
7. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
8. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
9. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... EVANSVILLE, Ind. , Sept. 16, 2014   ... builder of custom, automated assembly and test systems, recently ... for a leading medical device manufacturer. The Evana solution ... improve quality and ergonomics, as well as reduce labor. ... are automatically fed to Evana,s robotic assembly cell. The ...
(Date:9/16/2014)... 16, 2014   Vestagen Technical Textiles, Inc. ... at hospitals. The myComfort™ line of patient apparel is ... that is fluid repellant, breathable and in studies done ... of bacteria on the fabric i . ... the chain of transmission. We want myComfort to be ...
(Date:9/16/2014)... 16, 2014  Synereca Pharmaceutics, Inc. (SPI), ... active drugs that restore or increase the ... $1.4 million convertible debt financing. Accele Venture ... accelerator Accele Biopharma, Inc., led the financing ... recognized private not-for-profit corporation focused on growing ...
Breaking Medicine Technology:Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4
... Council (NPC) today welcomed global specialty biopharmaceutical company Shire ... senior vice president, specialty pharma R&D, will serve as ... "The last few years have brought change ... important questions unresolved.  For the pharmaceutical industry, how ...
... Medical, Inc., a Minnesota-based medical device company, has announced that ... eripheral F acilitated A ntegrade S teering ... O cclusions (PFAST-CTOs) study.  The company received approval from ... US based IDE for the peripheral devices and is now ...
Cached Medicine Technology:National Pharmaceutical Council Welcomes Shire as Its Newest Member 2BridgePoint Medical Announces US IDE Approval and First Patient Enrollment of Peripheral Chronic Total Occlusion Study 2
(Date:9/16/2014)... An experienced review website, Top10BestSEOHosting.com, has recently ... Bluehost and HostGator.com are among the best hosting ... high quality web hosting (including VPS and cloud ... now. , BlueHost ( http://www.bluehost.com/track/seohosts ) has ... a reliable and long-standing force in the world ...
(Date:9/16/2014)... The second federal bellwether trial involving ... subsidiary Ethicon concluded with the jury in the case ... her $3.27 million in damages, according to a September ... found Ethicon liable for selling faulty devices and failing ... at risk from side effects that include pain, bleeding ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... human papillomavirus (HPV), which is linked to the risk of ... that testing urine for HPV has good accuracy when compared ... lead researcher Dr. Neha Pathak. She is a resident in ... of London, England. The test could be done at ...
(Date:9/16/2014)... September 16, 2014 Not all recovery ... take care to make sure all their patients are ... some, this may include the newly-introduced online therapy. Millennium ... which gives patients the opportunity to seek treatment from ... provide medical and clinical care at a distance. They ...
(Date:9/16/2014)... in helping people to reach their fitness and ... wearers improve their wellness by constantly monitoring their ... into companion computer programs and mobile apps. ... for these devices, researchers at the University of ... these activity monitors, such as those made by ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: BlueHost and HostGator.com Are Among the Best Hosting Suppliers in 2014 2Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:Millennium Treatment Group Now Offers Online Therapy 2Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3
... , ST. LOUIS, Aug. 24 Recent developments ... have attorney and clean water advocate Steve Tillery cautiously optimistic ... for the herbicide,s manufacturers. , , "Just ... York Times and the Peoria Journal Star have underscored the ...
... attack and stroke, but also prevent them. Scientists at Heidelberg ... for the first time on an animal model. Mice with ... in their vessels, but they are more stable. Thus, there ... circulation. The results of the study have been published in ...
... (BRONX, NY) - Concussions, whether from an accident, sporting ... higher level mental processes. Scientists have debated for centuries ... whether physiological changes that merely impair the way brain ... time, researchers at Albert Einstein College of Medicine of ...
... New Rochelle, NY, August 24, 2009Twitter, the increasingly popular ... convenient way to stay in touch with friends and ... real-time, on-the-go communication of healthcare information and medical alerts, ... Connectivity section of the latest issue of Telemedicine ...
... signals future heart risk, researcher says. , MONDAY, Aug. 24 ... women may also show if they have an increased risk ... found. , This finding is important because doctors might be ... to identify women who are at risk for developing heart ...
... , , CINCINNATI Aug. 24 The Kroger ... it easy and affordable for customers to take steps to keep ... , , This year, Kroger,s more than 1,900 ... at an affordable price. Beginning in September, flu vaccines will ...
Cached Medicine News:Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 2Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 3Health News:Why 'thick' blood protects from a heart attack 2Health News:Strong link found between concussions and brain tissue injury 2Health News:Strong link found between concussions and brain tissue injury 3Health News:Twitter and health care -- can a tweet a day keep the doctor away? 2Health News:Glucose Challenge in Pregnancy Could Predict Heart Disease 2Health News:Kroger's Family of Pharmacies Offer Customers Easy and Affordable Seasonal Flu Vaccinations 2
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Sheath Introducers with guidewires....
Used to introduce balloon, electrode, closed or non-tapered end and,other catheters....
Medicine Products: